The Philadelphia-based CGT CDMO will support CIRM-funded innovators with end-to-end manufacturing and testing capabilities, reinforcing the critical role of partnership models in accelerating regenerative medicine.
In cell and gene therapy, breakthrough science is only half the battle. The other half — often less visible, but equally decisive — is manufacturing execution.
“CIRM plays a critical role in advancing CGT and accelerating therapies to patients,” said Eytan Abraham, CTO and CCO of Minaris. “By joining the IRP Program, we look forward to supporting CIRM’s network with flexible, scalable solutions tailored to the unique needs of emerging and growing cell and gene therapy programs.”
With that statement, Philadelphia-based Minaris signaled more than participation in a new network. It underscored a structural reality in advanced therapies: partnerships between funders and experienced CDMOs are becoming essential infrastructure for translational success.
Connecting Innovation to Infrastructure
Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider, has joined the California Institute for Regenerative Medicine’s (CIRM) Industry Resource Partner (IRP) Program. The program connects CIRM-funded research teams and companies with vetted service providers capable of accelerating development timelines and strengthening manufacturing strategies.
Through the IRP Program, Minaris will offer end-to-end CGT capabilities — from early-stage development and viral vector manufacturing to clinical and commercial GMP production, along with comprehensive biosafety, potency, viral clearance, and product characterization testing.
For CIRM awardees, this provides structured access to scalable manufacturing and regulatory expertise at a stage when speed, quality, and capital efficiency are often in tension.
Why Partnership Models Matter
For academic researchers and early-stage biotech founders, manufacturing is both mission-critical and capital-intensive. Building internal GMP capacity is rarely feasible early on. Yet delays in process development, tech transfer, or testing can erode investor confidence and shorten financial runway.
Programs like CIRM’s IRP model reduce that friction by embedding experienced CDMOs into the funding ecosystem. Rather than navigating vendor selection independently, innovators gain access to pre-aligned partners with relevant CGT expertise.
Minaris’ integrated service model supports innovators from process development through late-stage clinical trials and commercialization. That continuity helps reduce handoff risk — a common vulnerability in cell and gene therapy development, where complex manufacturing processes must scale under tight regulatory oversight.
In a funding environment increasingly focused on milestone discipline and risk mitigation, those efficiencies are more than operational advantages. They can determine whether a therapy reaches patients on schedule.
Philadelphia’s Growing CGT Backbone
While CIRM is based in California, Minaris’ participation reinforces the strength of the Greater Philadelphia region as a national cell and gene therapy hub.
Philadelphia has steadily expanded its advanced therapy footprint — from research institutions and startup formation to GMP manufacturing infrastructure and workforce development. As therapies move closer to commercialization, manufacturing depth becomes a defining regional asset.
Minaris brings more than 25 years of CGT development and manufacturing experience and over 40 years in biosafety testing, operating five global sites across three continents. Its presence in Philadelphia connects local infrastructure to a national funding network advancing regenerative medicine.
From Bench to Bedside — with Fewer Bottlenecks
Cell and gene therapies face unique scaling challenges, including complex viral vector production, stringent biosafety requirements, and individualized manufacturing models. Missteps can delay clinical trials and limit patient access.
By integrating CDMOs like Minaris into its ecosystem, CIRM’s IRP Program acknowledges that translational acceleration requires operational alignment alongside scientific discovery.
For early-stage innovators, these partnership frameworks offer more than outsourced services. They provide structured pathways from discovery to GMP production — helping ensure that promising science does not stall at the manufacturing threshold.
As Philadelphia continues to strengthen its advanced therapy infrastructure, Minaris’ role in the IRP Program reflects a broader industry truth: the future of regenerative medicine will be shaped not only by bold ideas, but by the partnerships capable of turning those ideas into deliverable therapies.
